Concord Medical Services Holdings Ltd: Form 20-F for the period ended Dec 31, 2025
Filed with the SEC on Apr 29, 2026 and accepted by EDGAR at Apr 29, 2026, 06:08 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2025-01-01 to 2025-12-31 | $65.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2025-01-01 to 2025-12-31 | $62.2m | us-gaap:CostOfRevenue |
| Gross profit | 12 months2025-01-01 to 2025-12-31 | $3.7m | us-gaap:GrossProfit |
| Operating income | 12 months2025-01-01 to 2025-12-31 | −$37.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2025-01-01 to 2025-12-31 | $21.8m | us-gaap:InterestExpenseNonoperating |
| Income tax | 12 months2025-01-01 to 2025-12-31 | $867.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2025-01-01 to 2025-12-31 | −$13.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2025-01-01 to 2025-12-31 | −$0.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2025-01-01 to 2025-12-31 | −$0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2025-01-01 to 2025-12-31 | 131,053,858 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2025-01-01 to 2025-12-31 | −$28.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2025-01-01 to 2025-12-31 | $8.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-12-31 | $42.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-12-31 | $134.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-12-31 | $936.3m | us-gaap:Assets |
| Current liabilities | At period end2025-12-31 | $279.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-12-31 | $671.7m | us-gaap:Liabilities |
| Long-term debt | At period end2025-12-31 | $352.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-12-31 | $78.7m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2025-12-31 | $61.5m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2025-12-31 | −$300.7m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2025-12-31 | 130,251,685 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001104659-26-050692. Last ingested by Listed: Oct 24, 2026, 15:08 ET. Listed shows no prices and gives no investment advice.